✉news WorldEU Politics first seen 1 d ago, last 12 h ago, peak #11

Hansoh's Tagrisso rival loses EU approval after AstraZeneca challenge

Original: Hansoh’s Tagrisso rival loses EU approval after AstraZeneca legal challenge

A copycat version of AstraZeneca's blockbuster lung cancer drug Tagrisso, made by China's Hansoh Pharmaceutical, has lost its European Union approval following a legal challenge from AstraZeneca. The decision removes the rival medicine from the EU market, marking a win for AstraZeneca in its defence of one of its biggest sellers.

Why now: AstraZeneca successfully used legal action to block a Chinese competitor to one of its most important cancer drugs in Europe.

Hansoh PharmaceuticalAstraZenecaEuropean UnionTagrisso

Open on news →

Rank over time, top of the chart is #1. 9 snapshots from 1 d ago to 12 h ago.

Evidence

• Hansoh’s Tagrisso rival loses EU approval after AstraZeneca legal challenge · fiercepharma.com

API: https://socialmediatrends-api.osmike.com/v1/trends/503879